Clinical and electrophysiological follow-up of modafinil treatment for multiple sclerosis patients with fatigue symptom

Abstract

Objectives: In our study, we investigated the effects of modafinil therapy on clinical and neurophysiological tests ofmultiple sclerosis (MS) patients with fatigue.Methods: The study was performed on 18 MS patients (16 females, 2 males) at Uludağ University School of Medicine,Department of Neurology, who are followed up according to Mc Donald’s criteria, who had 36 points or above basedon the fatigue assesment scala (FAS), whose Beck depression inventory points were 16 and below, whose thyroid,liver and renal functions were evaluated as normal, and who had no systemic disorder. All patients had neurologicalexamination and their expanded disability status scale (EDSS), fatigue impact scala (FIS) and multiple sclerosis qualityof life (MSQoL-54) were evaluated. Somatosensory evoked potential (SEP), visual evoked potential (VEP), brainstemauditory evoked potential (BAEP), visual event related evoked potential (visual P300) were performed in ourneurophysiology laboratory. After that the patients were given modafinil 100 mgr 1x1 (morning) for 1 week, thefollowing weeks 2x1 (morning and noon). At the end of the 6 weeks of therapy the patients were called to the neurologypolyclinic, and their neurological examinations, EDSS, FIS, MSQoL-54, SEP, VEP, BAEP and visual P300 wererepeated.Results: When the patients’ previous and subsequent FIS and MSQoL-54 total scores were compared, a significantstatistical difference was found. When all 3 subgroups of FIS (consciousness, physical and social) were evaluated afterthe modafinil therapy, a significant statistical decrease in previous and successive scores were found. It is found outthat modafinil therapy improves life quality which is evaluated due to MSQoL-54 (p 0.05).There were no statistically significant relation between the FAS, EDSS and Beck depression inventory scores beforethe modafinil therapy had been applied (p > 0.05). There was a statistically correlation between Beck depressioninventory score and FIS’s social subgroup (p = 0.017). When the patient’s SEP, VEP, BAEP, visual P300 average testvalues before and after the modafinil therapy were compared, a statistically significant difference was not observed.Conclusions: In our study, it is found that modafinil therapy, which is used against fatigue, one of the MS disase’smost common symptom, has a positive impact on MS life quality and patients’ clinical symptoms of fatigue, althoughit has no effect on patients’ evoked potential methods (BAEP, SEP, VEP, visual P300) performed in neurophysiology laboratory.